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Gynaecological schistosomiasis as a result of chronic infec-
tion with Schistosoma haematobium (commonly known 
as bilharzia) has been described in the medical literature 
since the 1940s.1,2 In the early 1970s researchers described 
a syndrome that was close to what is known today as female 
genital schistosomiasis,3,4 a term first used in the mid-1990s.5 
Female genital schistosomiasis is caused by an inflammatory 
reaction to schistosome eggs trapped in body tissue, leading 
to fibrosis and scarring of the female genital tract. Early signs 
of the disease are a burning sensation in the genitals, spot 
bleeding, abnormal discharge smell, bloody discharge, stress 
incontinence and lower abdominal pain.6 The disease can rap-
idly progress towards swellings or ulcerations of the vulva and 
vagina, causing genital bleeding, pain and dyspareunia.7 The 
symptoms can gradually evolve towards reproductive organ 
damage, characterized by sub- or infertility, ectopic pregnancy, 
spontaneous abortion, premature birth and low birth weight. 
The disease can therefore have serious sexual and reproductive 
health consequences for women in schistosomiasis-endemic 
areas, occurring primarily in poor populations in sub-Saharan 
Africa. Here we report on how female genital schistosomiasis 
has emerged as a concern, alongside HIV and cervical cancer, 
among the sexual and reproductive health issues affecting 
African girls and women.
Knowledge and gaps
Female genital schistosomiasis has not yet been reviewed 
or assessed as a specific entity, nor as part of the burden of 
schistosomiasis, by the Global Burden of Diseases Study.8 
Obtaining accurate disease burden information for the disease 
is daunting, given that the clinical awareness among health-
care workers is low, and its diagnosis is both cumbersome 
and complex. Additionally, the disease is not mentioned in 
most medical textbooks, or in the lay media, which further 
compounds the very low awareness and poor diagnosis of the 
condition, including among health workers.9 As a result, the 
disease has been largely ignored by national and global health 
policy-makers.10
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A standard diagnosis of female gen-
ital schistosomiasis requires colposcopy 
and histopathology and is often only 
conducted in well-equipped facilities 
that are not widely available in endemic 
areas. Community-based assessment 
of the disease burden is therefore chal-
lenging. Studies investigating the disease 
have been carried out in 18 countries in 
Africa, with a cumulative total of only 
10 332 women examined (Bustinduy A, 
London School of Hygiene and Tropical 
Medicine, September 2019, personal 
communication). In Nigeria the preva-
lence of female genital schistosomiasis in 
four schistosomiasis-endemic commu-
nities was 27.4% based on self-reported 
symptoms (87 of 317 women tested) and 
70.0% as confirmed by gynaecological 
examination (14 women in a subsample 
of 20).11 Detection of S. haematobium 
deoxyribonucleic acid in vaginal lavage 
has a good positive predictive value for 
genital lesions, especially during the 
earlier stages of female genital schis-
tosomiasis (70% overall, 77% in young 
women below the age of 25 years).12 The 
method offers diagnostic opportunities 
for further research and evaluation 
projects. In contrast, schistosome egg 
detection in urine, the gold standard 
diagnosis for urinary schistosomiasis, 
has a correlation of only 30% with the 
presence of genital lesions.12
A recent study in Zambia aimed to 
validate community-based diagnosis 
of female genital schistosomiasis by 
genital self-swabs. The prevalence of 
active schistosomiasis was 5.5% (33 
out of 603 women) as detected by urine 
microscopy and 15.1% (91 out of 601 
women) by circulating anodic antigen 
testing.13 However, 25.6% (135) of 527 
women tested were found to have female 
genital schistosomiasis as diagnosed by 
agreement among two imaging experts 
and a computer-assisted image analysis 
(Bustinduy A, Bilharzia and HIV Study, 
London School of Hygiene and Tropical 
Medicine, September 2019, personal 
communication). Urine-based assess-
ment of the occurrence of schistoso-
miasis in a community is not therefore 
a reliable proxy for the level of female 
genital schistosomiasis.
Female genital schistosomiasis 
has been suspected as a risk factor for 
the transmission of human immuno-
deficiency virus (HIV) for more than 
25 years, based on pathophysiological, 
immunological and epidemiological 
data.14,15 However, only in 2006 was 
an association between female genital 
schistosomiasis and HIV first reported 
based on field data.16 Since then, the 
scientific documentation of urogenital 
schistosomiasis as a potential risk factor 
for HIV has been strengthened.17–22 This 
evidence needs to be considered along 
with the strong possibility that lesions 
accompanying female genital schistoso-
miasis are potential entry points for HIV. 
Unfortunately, conducting randomized 
controlled trials or prospective stud-
ies may require withholding essential 
medicines for either schistosomiasis or 
HIV prevention and treatment. Ethical 
concerns therefore make it virtually 
impossible to design studies looking 
for a causal association. Most data on 
schistosomiasis and HIV interactions 
therefore come from retrospective or 
observational studies that examine ex-
isting sera sets. These gaps in research 
have resulted in mixed designs on mixed 
schistosome species with a mixture of 
outcomes that have precluded consensus 
on whether schistosomiasis affects HIV 
infection. Retrospective serological 
studies are limited due to the difficulty 
of determining a woman’s genital schis-
tosomiasis status or level of exposure to 
either schistosomiasis or HIV. Further-
more, few cross-sectional studies have 
focused specifically on female genital 
schistosomiasis because of the complex 
diagnostic procedures that are largely 
unsuitable in young adolescent girls. 
It is thus important to recognize that 
most studies of schistosomiasis–HIV 
co-infection do not specifically address 
female genital schistosomiasis. None-
theless, the retrospective evidence from 
past studies, coupled with strong biolog-
ical plausibility, are suggestive of a link 
between female genital schistosomiasis 
and increased risks of HIV acquisition.9 
While the link between HIV and 
human papilloma virus (HPV) has 
been the subject of a systematic review 
and meta-analysis,23 the evidence link-
ing female genital schistosomiasis with 
HPV infection and cervical cancer is 
less robust. Studies have found altered 
cervical mucosal gene expression and 
lower HPV- and cancer-protective 
interleukin-15 levels in women with S. 
haematobium infection and female geni-
tal schistosomiasis.24,25 This evidence, 
coupled with a strong geographical 
overlap of these three conditions, sug-
gests potential links among them.
At the local level, within communi-
ties and the health workforce, there are 
gaps in knowledge and understanding 
about female genital schistosomiasis 
prevention, treatment and control. 
Health-care providers can easily confuse 
the symptoms of the disease with those 
of sexually transmitted infections or 
cervical cancer. Incorrect diagnosis and 
management can have profound psy-
chosocial implications for pre-sexually 
active girls. The effect of the disease on 
fertility and pregnancy may have serious 
consequences for a woman’s relation-
ships with her family and community, of-
ten resulting in marginalization, stigma, 
isolation and the threat of gender-based 
violence.26 In specialized gynaecological 
or obstetric clinics, characteristic female 
genital schistosomiasis lesions may be 
noticed, but not attended to because of 
the narrow disease focus of the clinic 
and limited clinical awareness among 
health workers.
Rationale for an integrated 
approach
Female genital schistosomiasis is a seri-
ous gynaecological condition linked to 
pain, bleeding and severe social stigma 
in Africa. The consequences of the 
disease merit an urgent response in the 
broader sexual and reproductive health 
and rights agenda of girls and women in 
sub-Saharan Africa.27
Women and girls face multiple and 
intersecting health, social, gender and 
economic challenges, especially in the 
poorest and most marginalized and 
fragile parts of our world. Many, if not 
most of these women and girls in sub-
Saharan Africa carry a triple burden of 
vulnerability to HIV, HPV/cervical can-
cer and female genital schistosomiasis. 
There is mounting evidence for a three-
way interaction between these diseases 
and that controlling one may decrease 
the risk of unwanted outcomes for the 
two others.17–25 Each of the diseases 
has a targeted and proven preventive 
intervention: antiretroviral therapy 
and pre-exposure prophylaxis for HIV; 
the HPV vaccine for cervical cancer; 
and praziquantel treatment for female 
genital schistosomiasis. It is therefore 
logical and practical to break down the 
disease-specific approaches and aim 
for programmatic integration, using 
existing opportunities to reach girls and 
women throughout their life course. The 
benefits of such an integrated approach 
should be straightforward to docu-
ment. Yet global health policy-makers, 
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implementing partners and operational 
research initiatives still mostly separate 
female genital schistosomiasis from both 
HIV and cervical cancer prevention and 
treatment or care efforts. This lack of ac-
tion happens despite the largely similar 
demographics of the women and girls 
affected by the three diseases and is a 
missed opportunity to galvanize action 
and expand access to prevention and 
treatment.
High-level meeting
A high-level meeting was held to break 
the deadlock to large-scale implementa-
tion of female genital schistosomiasis 
interventions and to facilitate an inte-
grated approach with HIV and cervical 
cancer prevention and care. Over a 
hundred international experts gathered 
on the side-lines of the 11th European 
Congress on Tropical Medicine and In-
ternational Health in September 2019.28 
The group called for immediate action 
to address this important and neglected 
sexual and reproductive health and 
rights issue affecting the lives of millions 
of sub-Saharan African women and 
girls. A need was identified to strengthen 
primary health care to promote access to 
praziquantel for girls and women at risk 
of schistosomiasis infection. The group 
also reiterated the demand for the full 
integration of interventions for female 
genital schistosomiasis with HIV and 
HPV/cervical cancer prevention and 
control in a comprehensive sexual and 
reproductive health package. As a result, 
the meeting focused on advancing the 
implementation science and strongly 
encouraged national researchers to take 
charge of operational research agendas 
for integrated delivery. The meeting also 
looked at efforts to address the social 
determinants of health and improve 
access to safe water and sanitation to 
reduce contact with infested waters for 
all those women at current or future risk.
Operational research to facilitate 
implementation
The operational research needs that 
were highlighted during the meeting 
included: (i) community-level burden 
assessment of female genital schis-
tosomiasis; (ii) strategies for ensur-
ing regular praziquantel treatment of 
women and girls outside of school-based 
deworming programmes; (iii) clinical 
treatment protocols for existing female 
genital schistosomiasis; (iv) strategies 
to improve awareness of female genital 
schistosomiasis and community engage-
ment with the issue; and (v) impact 
evaluation and economic analysis of 
integrated strategies versus separate, 
parallel approaches.
Community-level burden assessment
The Bilharzia and HIV study is currently 
evaluating genital self-swabbing as a 
potential low-cost approach to commu-
nity-based diagnosis for female genital 
schistosomiasis in Zambia.13 While this 
approach offers enhanced opportunities 
for research and impact evaluation stud-
ies, it is unlikely to trigger a large-scale 
investigation of the female genital schis-
tosomiasis burden. We can ask: is such 
a global or regional burden assessment 
necessary? At the high-level meeting,28 
voices from experts working in the field 
confirmed that the public health rel-
evance of the disease is easily revealed by 
its occurrence in gynaecological practice 
(Gamba V, University of Nairobi, 2019, 
personal communication) or qualita-
tive methods in communities (Masong 
M, Catholic University of Central Af-
rica, 2019, personal communication). 
Such information can be combined 
with capacity-building of the health 
workforce in diagnosing female genital 
schistosomiasis and the wider use of 
data platforms in local health services, 
including health centres equipped to 
test and treat cervical cancer. If so, the 
information should provide enough 
evidence to trigger programmatic in-
tegration. Key to the success of such 
a primary health-care approach is the 
establishment of a clear case definition 
of female genital schistosomiasis and the 
validation of diagnostic algorithms that 
need to be distributed for use in front-
line health services.
Strategies for ensuring regular treatment
Chronic female genital schistosomiasis 
lesions can be prevented by regular 
treatment with praziquantel started at 
an early age, such as through primary 
school-based deworming programmes,29 
and continued in later life at all avail-
able opportunities. Encouragingly, in 
addition to praziquantel for school-age 
children (donated free of charge in 
sub-Saharan Africa by Merck KGaA, 
Darmstadt, Germany), access to the 
treatment has recently been extended 
to selected groups of adults. There are 
also ongoing efforts to make a paedi-
atric formulation widely available to 
preschool children. Yet, further opera-
tional research is needed to optimize op-
portunities for large-scale treatment of 
women and girls beyond deworming in 
school health programmes; for ensuring 
regular treatment of girls and women 
with praziquantel through the primary 
health-care system; or for test-and-treat 
approaches during early childhood or 
from adolescence onwards. An impor-
tant component of this work includes 
better ways to diagnose schistosomiasis 
and female genital schistosomiasis in 
sexual and reproductive health and 
rights programmes. The urine dipstick 
for microscopic haematuria is currently 
the best proxy for diagnosis of urinary 
schistosomiasis. However, more sensi-
tive rapid diagnostic tests based on 
antigen detection in urine are under 
development and will facilitate test-and-
treat approaches in children younger 
than 5 years, adolescent girls and young 
women. Combined packages of rapid 
diagnostic tests and treatment could 
be tailored for use in health services 
and programmes. Clinical diagnosis of 
female genital schistosomiasis would be 
improved if links could be established 
with health-care facilities that provide 
cervical cancer screening programmes. 
While the aim of the current paper is to 
focus on female genital schistosomiasis, 
these principles are valid too for male 
genital schistosomiasis.30
Clinical treatment protocols
While its preventive effect is well 
documented, it is less clear whether 
praziquantel treatment at the standard 
dose improves established genital dis-
ease. In the Bilharzia and HIV Study in 
Zambia of women aged 18–31 years, the 
frequency of six female genital schisto-
somiasis-related symptoms all declined 
by 5 to 10 percentage points after a single 
dose (Bustinduy A, London School of 
Hygiene and Tropical Medicine, 2019, 
personal communication). This finding 
is consistent with the partial resolution 
of lesions observed in Malawi,31 South 
Africa32 and Zimbabwe33 after standard 
praziquantel treatment. However, we 
need additional research to determine 
the optimal clinical treatment of female 
genital schistosomiasis, potentially with 
higher and more prolonged doses of 
praziquantel, with or without additional 
anti-inflammatory drugs. The results 
will inform the revision of treatment 
guidelines and curricula in training 
institutions.
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Strategies to improve awareness
Box 1 presents several questions sur-
rounding the perception of female 
genital schistosomiasis as a prevailing 
sexual and reproductive health and 
rights problem.
All these are operational research 
questions that biomedical and social 
science researchers will need to jointly 
answer. Many lessons can be drawn from 
the experience of HIV with regards to 
mobilizing and engaging communities, 
amplifying the call for integrated ser-
vices and creating demand for service 
and commodities to address the specific 
needs of women and girls when and 
where they need them.36
Impact evaluation and economic analysis
More studies to strengthen the evidence 
base for a cause-and-effect relationship 
among female genital schistosomiasis, 
HIV and HPV/cervical cancer would 
clearly be useful. Randomized controlled 
trial evidence would be ideal, but proven 
and well-established interventions are 
available for each of these diseases and 
cannot be withheld in a trial setting. 
Although research on neglected tropical 
diseases remains relatively underfunded, 
the lack of robust evidence should not 
be a deterrent to moving forward. Close 
monitoring and evaluation of the impact 
of a comprehensive response on all three 
diseases could potentially be nested 
into ongoing population-based impact 
assessment and evaluation efforts. The 
data should provide the answer to the 
question of whether implementation of 
the packages of care provides enhanced 
benefits, should be scaled up and offers 
opportunities for economies of scale.
Three diseases: one 
integrated response
The physical and psychosocial impact 
of female genital schistosomiasis, along 
Box 1. Questions surrounding the perception of female genital schistosomiasis as a 
prevailing sexual and reproductive health and rights problem
• How can we mobilize and engage communities, health services and their workforce so that 
female genital schistosomiasis is understood and acted upon appropriately and stigma is 
avoided? 
• What are the enabling factors and barriers for the integration of female genital 
schistosomiasis, HIV and HPV/cervical cancer in sexual and reproductive health and rights 
programmes at the community level? 
• How can we rapidly build the capacity of the skilled health workforce, front-line health 
workers and school teachers to become agents of change in favour of fair and comprehensive 
sexual and reproductive health and rights programmes? 
• How can we increase community awareness of female genital schistosomiasis prevention, 
treatment and control and meaningfully engage sexual and reproductive health and rights 
and HIV activists? 
• How can community activists become advocates within their communities and agents of 
demand for inclusive, non-stigmatizing, integrated and comprehensive services? 
• How can community awareness and demand creation influence policy changes to address 
the issues of safe water and behavioural change to prevent schistosomiasis?34,35
HIV: human immunodeficiency virus; HPV: human papilloma virus.






Provision of safe water.
Behavioural change
Integrated, people-centred 
care. Treatment and referral.
Health workforce training.






































for established female 
genital schistosomiasis
Community-level 
burden assessment of 
female genital 
schistosomiasis
ART: antiretroviral therapy; HIV: human immunodeficiency virus; HPV: human papilloma virus; STIs: sexually transmitted infections.
Note: Boxes indicate where operational research goals will create opportunities for further improvement or evidence-building. 
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with the potential links across the three 
priority genital diseases, position female 
genital schistosomiasis as a pillar in a 
comprehensive sexual and reproductive 
health and rights agenda for women 
and girls in Africa.37 Despite the many 
unanswered questions, integrated action 
with the currently available tools and 
practices is highly needed and possible. 
We have summarized a conceptual 
framework for the integrated program-
matic implementation of the three 
diseases (Fig. 1). The framework can be 
further tailored to include screening, 
treatment or referral for other common 
female genital diseases or complications 
of other infections, such as genital tu-
berculosis.
Although female genital schis-
tosomiasis is preventable by regular 
treatment, too often praziquantel is not 
available within the primary health-care 
system outside of school-based, large-
scale treatment.38 Many girls and women 
who do not attend schools are therefore 
missed. An integrated response to fe-
male genital schistosomiasis, HIV and 
cervical cancer is likely to boost access 
to praziquantel treatment for girls and 
women beyond primary schooling.
Established female genital schis-
tosomiasis can be diagnosed during 
screening for cervical cancer, such as 
colposcopy and visual inspection of 
the cervix with acetic acid. The World 
Health Organization (WHO) has pro-
duced a visual aid to facilitate recogni-
tion of female genital schistosomiasis 
by clinical health-care professionals.39 
Table 1. Programmatic integration of the prevention and treatment of HIV, sexually transmitted infections, cervical cancer and female 
genital schistosomiasis in regions endemic for Schistosoma haematobium 





and female genital 
schistosomiasis 
interventions








Ante-, peri- and 
postnatal care. 

















mothers and children 











treatment in highly 
endemic areas.
NA Counselling for mothers on HIV 
prevention. 
Promotion of behavioural change 
for prevention and treatment of 
schistosomiasis. Topics to include 
safe bathing practices for infants 
and children. 
Awareness-building and 
information on HIV, schistosomiasis, 
female genital schistosomiasis and 
HPV/cervical cancer. 
Dialogue with mothers and 
caregivers about signs and 
symptoms of female genital 
schistosomiasis, sexually 
transmitted infections and cervical 
cancer. Referral to appropriate 
services if indicated. 
Community-based outreach, 
including generation of demand 
for accessible treatment and for 
improved water and sanitation 
services. Examples include: through 
community health clubs and 










targeting or including 
children not enrolled 
in school.
NA Regular treatment 
with praziquantel as 
part of deworming 
programmes. 
Frequency 
according to level of 
endemicity and WHO 
recommendations. 
Possible extension 
of deworming to 
siblings and non-
enrolled school-age 
children in same 
communities. 
Safe water and 
(girl-friendly and 




of HPV vaccination 




age range in same 
communities.
Education about schistosomiasis, 
communicable diseases or other 
tropical diseases in the area. 
Age-appropriate, comprehensive 
health, sexual and reproductive 
health and rights and life-skills 
education. Topics to include: HIV, 
female genital schistosomiasis and 
cervical cancer. 
Hygiene education, including 
menstrual hygiene for girls.
(continues. . .)
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The pocket atlas also allows inclusion 
of the disease in guidelines and training 
modules for the syndromic management 
of sexually transmitted infections and 
encourages parallel screening for HIV, 
sexually transmitted infections and cer-
vical cancer.40 Furthermore, recognizing 
the need for an integrated response, 
the WHO and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 
developed a joint advocacy brief in 2019. 
The document aims to increase knowl-
edge and awareness of female genital 
schistosomiasis among policy-makers 
and affected communities, encourag-
ing programmatic integration in areas 
endemic for urogenital schistosomia-
sis.41 The joint advocacy brief is similar 
to the 2016 UNAIDS advocacy brief on 
HIV and HPV cervical cancer.42 This 
earlier document has successfully mo-
bilized civil society, notably sexual and 
reproductive health and rights activists 
and women living with HIV, to engage 





and female genital 
schistosomiasis 
interventions













both in and out 







Refer to health 
services for 
further care if 
indicated.
Discussion about 
girl’s risk of 
schistosomiasis. Test-






treatment in areas 






aware and age-appropriate 
comprehensive sexual and 
reproductive health and rights 
education. Topics to include: HIV, 
sexually transmitted infections, 
female genital schistosomiasis 
and cervical cancer. Referral to 
appropriate services if indicated. 
Hygiene education, including 
menstrual hygiene for girls. 
Age-appropriate comprehensive 
sexuality education. Topics to 
include: counselling on condom 
use, negotiating skills relating to 
sexual interactions and safe-sex 
practices. 
Community-based outreach, 
including generation of demand 
for comprehensive sexual and 




Prenatal care and 














services. Refer to 
health services 







against HIV is 
indicated.
Discussion about 
woman’s risk of 
schistosomiasis. Test-




risk of female genital 
schistosomiasis. Refer 
to health services or 
cervical cancer clinics 
for further screening 
and care if indicated. 













Provide and facilitate 





for female genital 
schistosomiasis 
in cervical cancer 
screening services.
Provide information on symptoms 
and risks of HIV infection, sexually 
transmitted infections and female 
genital schistosomiasis. 
Query women about signs and 
symptoms of female genital 
schistosomiasis, sexually 
transmitted infections and cervical 
cancer. Facilitate referral to 
appropriate services if indicated. 
Hygiene education, including 
menstrual hygiene for women. 
Train physicians to begin 
colposcopy for women at 
younger ages and to recognize, 
diagnose and treat female genital 
schistosomiasis. 
Community-based outreach, 
engagement and generation of 
demand for comprehensive sexual 
and reproductive health and rights 
services in existing community-
based structures. Examples include: 
women’s groups, mother and child 
health clinics and village health 
clubs.
HIV: human immunodeficiency virus; HPV: human papilloma virus; NA: not applicable; WHO: World Health Organization. 
a  Antigen-based urine dipstick is under development.
b  Paediatric formulation of praziquantel is under development. 
c  Examples include the Adolescents and Youth Program43 and the DREAMS partnership.44
Note: Adapted from WHO and Joint United Nations Programme on HIV/AIDS, 2019.41
(. . .continued)
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in and influence the WHO initiative 
to eliminate cervical cancer as a public 
health problem.
Preventive interventions for HIV, 
cervical cancer and female genital schis-
tosomiasis can all be successfully deliv-
ered through existing programmes. An 
integrated programme would strengthen 
health systems and make a compelling 
case for a strategic change towards 
comprehensive sexual and reproductive 
health and rights services in affected 
regions (Table 1). A pragmatic opera-
tional research agenda has the potential 
to optimize joint implementation. As 
improved tools and practices are devel-
oped, sustained access to them will be 
needed in resource-poor environments. 
In this respect, we can draw lessons 
from the various models that have been 
developed and implemented to ensure 
access to medicines and diagnostics for 
neglected tropical diseases.
Conclusion
Several relevant global initiatives are 
already in place: the sustainable de-
velopment goals, including universal 
health coverage;36 the 2016 United 
Nations political declaration on HIV;45 
the HIV prevention 2020 road map46 
and the H6 partnership to advance 
the Every Woman Every Child global 
strategy.47 The current global health 
environment offers opportunities to 
combine disease-specific initiatives; 
strengthen health systems at all levels 
to provide integrated, comprehensive 
and quality services; and to address the 
multifaceted and intersecting health, 
sociocultural, gender and economic 
issues facing women and girls. Inte-
grated approaches, which have a strong 
rights-based approach, and which join 
up multiple public health programmes, 
create new opportunities and expand 
existing ways to reach more girls and 
women throughout their life span. In ad-
dition, an integrated approach provides 
opportunities to mobilize new resources 
and use existing resources more effec-
tively. Building on lessons learnt from 
the response to the HIV epidemic, we 
need to expand and diversify partner-
ships beyond the traditional biomedical 
public health communities to engage 
advocates for sexual and reproductive 
health rights and women’s rights. Such 
expanded partnerships will help to po-
sition comprehensive prevention and 
control of female genital schistosomia-
sis, HIV and cervical cancer within the 
broader sexual and reproductive health 
and rights, women’s empowerment and 
social justice framework. ■
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محرلا قنع ناطسرو ةيشربلا ةعانلما صقن سويرفو ،ةيوثنلأا ةيلسانتلا ايسراهلبلا ءاد لىع ةرطيسلا تاءارجإو ةياقولا جمد
 ةنمزلما  ةباصلإل  ةجيتنك  ةيوثنلأا  ةيلسانتلا  ايسراهلبلا  ءاد  نإ
 هضرعت في رمتسي ،(ايسراهلبلا مساب ةفورعلما) ةيومدلا ايسراهلبلاب
 ةيحصلا  تاسايسلا  يعضاو  بناج  نم  يربك  دح  لىإ  لهاجتلل
 عساو  قاطن  لىع  لمعلل  ليودلا  مماتهلاا  زكري  .ةيلماعلاو  ةينطولا
 صقن  سويرف  لاقتنلا  رطخ  لماع  ناك  اذإ  ام  لىع  ضرلما  دض
 ةيوثنلأا  ةيلسانتلا  ايسراهلبلا  ءاد  نإ  لاإ  .(HIV)  ةيشربلا  ةعانلما
 لىإ يدؤي وأ ،ةبوصلخا مدع وأ مقعلاو فيزنلاو لملأاب طبتري هسفن
 قطانلما  في ءاسنلل  ةبسنلاب  ةعئاش ةلكشم وهو ،يعماتجلاا  مصولا
 .ىبركلا ءارحصلا بونج ةيقيرفلأا لودلا في ايسراهلبلاب ةءوبولما
 تانوكم  نم  رخآ  نوكمك  ضرلماب  فاترعلاا  بيج  كلذ  لىعو
 في تايتفلاو ءاسنلل ناسنلإا قوقحو ةلماشلا ةحصلا لماعأ لودج
 ناطسرو HIV)) ةيشربلا ةعانلما صقن سويرف بناج لىإ ،ايقيرفأ
 يئاقو  لخدت  اله  ةثلاثلا  ضارـملأا  هذه  نم  لك  .محرلا  قنع
 ،ةيرقهقلا  تاسويرفلا  تاداضمب  جلاعلا  وهو :تبثمو  فدهتسم
 حاقل ؛زديلإا/ةيشربلا ةعانلما صقن سويرفل ضرعتلا لبق ةياقولاو
 جلاعو  ؛محرلا  قنع  ناطسرل  يشربلا  يميللحا  مرولا  سويرف
 شقانن  نحن  .ةيوثنلأا  ةيلسانتلا  ايسراهلبلا  ضرلم  ليتناوكيزابرلا
 عم ،ةيوثنلأا ةيلسانتلا ايسراهلبلا ءاد لىع ةرطيسلا جمد نكمي فيك
 .محرلا قنع ناطسرو ،زديلإا /ةبستكلما ةيشربلا ةعانلما صقن ةياعر
 قوقلحاو ةحصلل عسوأ لمع راطإ نم ًاءزج جمانبرلا اذه نوكيس
 .ايقيرفأ  في  ةيعماتجلاا  ةلادعلاو  ةأرلما  ينكتمو  ،ةيباجنلإاو  ةيسنلجا
 ،ةماعلا  ةحصلا  جمارب  نم  ديدعلا  لمشت  يتلا  ةلماكتلما  جهنلا  نإ
 نم  ديزلما  لىإ  لوصولل  صرف  قلخ  وأ  عيسوت  لىع  ةردقلا  ايهدل
 لماعأ  لودج  زجون  نحن  .نتهايح  تاترف  لاوط  ءاسنلاو  تايتفلا
 نم ةمزلح كترشلما ذيفنتلا ينستح ةيناكمإ هيدل ،ليمع لييغشت يثحب
.ءاسنلاو تايتفلل ةددحلما تاجايتحلال بيجتست يتلا يربادتلا
622 Bull World Health Organ 2020;98:615–624| doi: http://dx.doi.org/10.2471/BLT.20.252270
Policy & practice
Female genital schistosomiasis, HIV and cervical cancer Dirk Engels et al.
疾病中的每一种都有针对性和经过验证的预防性干预











Intégration des mesures de prévention et de contrôle de la schistosomiase génitale féminine, du VIH et du cancer du col de 
l’utérus
La schistosomiase génitale féminine, résultant d’une infection chronique 
à Schistosoma haematobium (également connue sous le nom de 
bilharziose), continue d’être largement ignorée par les responsables 
des politiques de santé nationales et internationales. Si le monde lui 
accorde son attention en vue de mener une action à grande échelle 
contre la maladie, c’est surtout pour déterminer s’il s’agit d’un facteur 
de risque pour la transmission du virus de l’immunodéficience humaine 
(VIH). Pourtant, la schistosomiase génitale féminine est associée à 
des douleurs, des saignements et peut engendrer l’hypofertilité, 
voire la stérilité. Par conséquent, celles qui en souffrent sont souvent 
stigmatisées, et le problème est courant dans les régions endémiques 
d’Afrique subsaharienne. Cette maladie doit donc être considérée 
comme composante à part entière d’une approche globale de la santé 
et des droits humains pour les femmes et filles africaines, à l’instar du 
VIH et du cancer du col de l’utérus. Chacune de ces trois maladies fait 
l’objet d’une intervention préventive ciblée qui a déjà fait ses preuves: 
le traitement antirétroviral et la prophylaxie pré-exposition pour le 
VIH; le vaccin contre le papillomavirus humain pour le cancer du col 
de l’utérus; et l’administration de praziquantel pour la schistosomiase 
génitale féminine. Le présent document se penche sur la manière 
d’intégrer la schistosomiase génitale féminine dans la prise en charge 
du VIH et du cancer du col de l’utérus. Un tel programme fera partie 
d’un cadre plus vaste consacré aux droits et à la santé sexuelle et 
reproductive, à l’émancipation des femmes et à la justice sociale en 
Afrique. Les approches intégrées qui regroupent plusieurs programmes 
de santé publique permettent d’élargir des perspectives ou de créer des 
opportunités visant à atteindre un plus grand nombre de filles et de 
femmes tout au long de leur vie. Nous exposons les grandes lignes d’un 
programme de recherches pragmatiques et opérationnelles capable 
d’optimiser la mise en œuvre conjointe d’une série de mesures qui 
répondent aux besoins spécifiques des filles et des femmes.
Резюме
Интеграция мер профилактики и контроля заболеваемости генитальным шистосомозом, ВИЧ и раком 
шейки матки
Генитальный шистосомоз у женщин в результате хронической 
инфекции, вызванной паразитом Schistosoma haematobium (более 
распространенное название — бильгарция), по-прежнему 
обходят вниманием при принятии решений в сфере 
здравоохранения как на национальном, так и на мировом 
уровне. Международное внимание к крупномасштабным 
мероприятиям по борьбе с заболеванием сосредоточено 
вокруг вопроса, является ли бильгарциоз фактором риска при 
передаче вируса иммунодефицита человека (ВИЧ). Но и сам по 
себе шистосомоз у женщин связан с болью, кровотечениями, 
нарушениями фертильности или бесплодием, что ведет к 
социальной стигматизации, которая очень распространена 
среди женщин в регионах, эндемичных по шистосомозу (к 
югу от Сахары). Следовательно, данное заболевание следует 
рассматривать в качестве компонента комплексной системы по 
охране здоровья и прав человека у женщин и девочек в Африке 
наряду с ВИЧ и раком шейки матки. Для каждого из этих трех 
заболеваний существуют целенаправленные и надежные методы 
профилактики: антиретровирусная терапия и доконтактная 
профилактика для ВИЧ, вакцинация против вируса папилломы 
человека для рака шейки матки и лечение празиквантелом 
для женского генитального шистосомоза. Авторы обсуждают 
возможность интеграции мер по контролю заболеваемости 
женским генитальным шистосомозом в схему медицинской 
помощи при ВИЧ и раке шейки матки. Такая программа 
станет частью более широкой концепции сексуального и 
репродуктивного здоровья и прав человека, расширения прав и 
возможностей женщин и социальной справедливости в Африке. 
Интегрированный подход, объединяющий многочисленные 
программы общественного здравоохранения, может расширить 
или создать новые возможности для более широкого охвата 
женщин и девочек на протяжении их жизни. Авторы описывают 
практичный план операционных исследований, который может 
помочь в оптимизации совместного внедрения пакета мер, 
отвечающих конкретным потребностям девочек и женщин.
Resumen
Integración de las medidas de prevención y control de la esquistosomiasis genital femenina, el VIH y el cáncer de cuello uterino
Los responsables de formular las políticas sanitarias nacionales y 
globales siguen ignorando en gran medida la esquistosomiasis 
genital femenina como consecuencia de la infección crónica por 
Schistosoma haematobium (conocida comúnmente como bilharziasis). 
La atención internacional para adoptar medidas de gran alcance contra 
la enfermedad se centra en determinar si es un factor de riesgo para 
la transmisión del virus de la inmunodeficiencia humana (VIH). Sin 
embargo, la propia esquistosomiasis genital femenina está vinculada 
al dolor, las hemorragias y la infertilidad o subfertilidad, lo que conduce 
al estigma social, además de ser un problema común para las mujeres 
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de las áreas en donde la esquistosomiasis es endémica en el África 
subsahariana. Por consiguiente, la enfermedad debe ser reconocida 
como otro componente de un programa integral de salud y de 
derechos humanos para las mujeres y las niñas de África, junto con el 
VIH y el cáncer de cuello uterino. Cada una de estas tres enfermedades 
tiene una intervención preventiva específica y comprobada: la terapia 
antirretroviral y la profilaxis previa a la exposición para el VIH; la vacuna 
contra el virus del papiloma humano para el cáncer de cuello uterino; y el 
tratamiento con praziquantel para la esquistosomiasis genital femenina. 
Se analiza cómo el control de la esquistosomiasis genital femenina se 
puede integrar con la atención del VIH y el cáncer de cuello uterino. Ese 
programa formará parte de un marco más amplio de salud y de derechos 
sexuales y reproductivos, de empoderamiento de la mujer y de justicia 
social en África. Los enfoques integrados que unen múltiples programas 
de salud pública tienen el potencial de ampliar o crear oportunidades 
para llegar a más niñas y mujeres a lo largo de sus vidas. Se describe a 
grandes rasgos un programa de investigación operacional pragmático 
que tiene el potencial de optimizar la implementación conjunta de una 
serie de medidas que respondan a las necesidades específicas de las 
niñas y de las mujeres.
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